Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Trial Profile

A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Clofarabine (Primary) ; Cytarabine (Primary) ; Arsenic trioxide; Azacitidine; Cytarabine; Daunorubicin; Gemtuzumab ozogamicin; Tipifarnib
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms AML-16
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 May 2014 According to United Kingdom Clinical Research Network record the accrual to date is 139%
    • 09 Jul 2013 Results for the low-dose cytarabine vs clofarabine randomisation in older patients published in Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top